Psychedelics Companies Share Corporate Updates: Numinus, Delix, Tryp And Small Pharma

Numinus Updates On New Acquisition’s Integration And Provides Client Financing Options

Numinus Wellness Inc. (OTCQX: NUMIF) recently acquired psychedelics company Novamind and is successfully integrating its activities: US clinics performed solidly while client appointments grew during fiscal Q4 (the three months ended August 31, 2022). Numinus mental health care services include traditional therapy, counseling, Transcranial Magnetic Stimulation (TMS), ketamine-assisted therapy (KAT), and Canada's SAP-approved cases of psychedelic-assisted therapy. During August, clinics in Canada and the US held more than six thousand patient appointments altogether, reflecting a 25% growth compared to July. Specifically, the eight US wellness clinics received almost five thousand clients. 15% of sych clients were new patients, representing an increase of 22% from the prior month. As to the treatments required, ketamine sessions at the company’s US clinics (including KAT, spravato and ketamine medicine) grew 35% in August, compared to July, to 1,520 appointments, while demand for TMS services grew 23% in August compared to July, to 725 appointments. Former Novamind clinical trial management division Cedar Clinical Research ... Full story available on Benzinga.com ketamine psychedelic therapy psychedelics financing novamind numinus wellness numinus tryp small pharma delix research

Read More